Celator Pharmaceuticals Inc., an oncopharmaceutical company with offices in Vancouver and Princeton, N.J., has raised US$10 million in Series C funding. Return backers include Domain Associates, Quaker BioVentures, TL Ventures, Ventures West Management, GrowthWorks, the Business Development Bank of Canada and Healthstone Investment Ltd. Celator has now raised $57 million in total VC funding since 2003. www.celatorpharma.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
Copyright PEI Media
Not for publication, email or dissemination
Share with other subscribers
Only logged in subscribers of this site will be able to access the shared article.